TrimebutineAntimuscarinic CAS# 39133-31-8 |
- Gimeracil
Catalog No.:BCC2296
CAS No.:103766-25-2
- Mycophenolate Mofetil
Catalog No.:BCC2290
CAS No.:128794-94-5
- AGI-5198
Catalog No.:BCC2293
CAS No.:1355326-35-0
- AGI-6780
Catalog No.:BCC1331
CAS No.:1432660-47-3
- CPI-613
Catalog No.:BCC2287
CAS No.:95809-78-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 39133-31-8 | SDF | Download SDF |
| PubChem ID | 5573 | Appearance | Powder |
| Formula | C22H29NO5 | M.Wt | 387.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | [2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate | ||
| SMILES | CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C | ||
| Standard InChIKey | LORDFXWUHHSAQU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Trimebutine Dilution Calculator
Trimebutine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5808 mL | 12.9042 mL | 25.8084 mL | 51.6169 mL | 64.5211 mL |
| 5 mM | 0.5162 mL | 2.5808 mL | 5.1617 mL | 10.3234 mL | 12.9042 mL |
| 10 mM | 0.2581 mL | 1.2904 mL | 2.5808 mL | 5.1617 mL | 6.4521 mL |
| 50 mM | 0.0516 mL | 0.2581 mL | 0.5162 mL | 1.0323 mL | 1.2904 mL |
| 100 mM | 0.0258 mL | 0.129 mL | 0.2581 mL | 0.5162 mL | 0.6452 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain. The major product
- N-Me-Ala-OH.HCl
Catalog No.:BCC2619
CAS No.:3913-67-5
- PD0325901
Catalog No.:BCC1277
CAS No.:391210-10-9
- PD318088
Catalog No.:BCC2539
CAS No.:391210-00-7
- Nigranoic acid
Catalog No.:BCN2399
CAS No.:39111-07-4
- Ajmalan-17-one
Catalog No.:BCN3519
CAS No.:3911-19-1
- Karakoline
Catalog No.:BCC8331
CAS No.:39089-30-0
- UCM 707
Catalog No.:BCC7217
CAS No.:390824-20-1
- Ingenol 20-palmitate
Catalog No.:BCN7678
CAS No.:39071-33-5
- GS 39783
Catalog No.:BCC7233
CAS No.:39069-52-8
- Buxbodine D
Catalog No.:BCN5448
CAS No.:390362-53-5
- Buxbodine B
Catalog No.:BCN5447
CAS No.:390362-51-3
- 9-Methoxycamptothecine
Catalog No.:BCN1219
CAS No.:39026-92-1
- Ac-His-OH.H2O
Catalog No.:BCC2953
CAS No.:39145-52-3
- (E)-Cinnamyl-(Z)-p-coumarate
Catalog No.:BCN7694
CAS No.:391682-51-2
- Oxyresveratrol 2-O-beta-D-glucopyranoside
Catalog No.:BCN1448
CAS No.:392274-22-5
- Ginsenoside Compound K
Catalog No.:BCN1246
CAS No.:39262-14-1
- Sotalol
Catalog No.:BCC4356
CAS No.:3930-20-9
- Tiplaxtinin(PAI-039)
Catalog No.:BCC6439
CAS No.:393105-53-8
- 2,3-Dihydroxy-4-methoxybenzoic acid
Catalog No.:BCN6534
CAS No.:3934-81-4
- BCTC
Catalog No.:BCC7797
CAS No.:393514-24-4
- Neurotensin
Catalog No.:BCC5842
CAS No.:39379-15-2
- Kamebanin
Catalog No.:BCN5449
CAS No.:39388-57-3
- Ethyl 3,4-dihydroxybenzoate
Catalog No.:BCN8504
CAS No.:3943-89-3
- Eleutheroside E
Catalog No.:BCN1083
CAS No.:39432-56-9
A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice.[Pubmed:26541237]
Eur J Pain. 2016 May;20(5):723-30.
BACKGROUND: Trimebutine maleate, a noncompetitive spasmolytic agent with some affinity for peripheral mu- and kappa-opioid receptors has been evaluated as a treatment in a limited number of patients undergoing sedation-free full colonoscopy. The efficiency of such treatment was comparable to sedation-based colonoscopies to relieve from pain and discomfort. METHODS: A new and improved Trimebutine salt capable of releasing in vivo hydrogen sulphide (H2S), a gaseous mediator known to reduce nociception, has been developed. This drug salt (GIC-1001) is composed of Trimebutine bearing a H2S-releasing counterion (3-thiocarbamoylbenzoate, 3TCB), the latter having the ability to release H2S. GIC-1001 has been tested here in a mouse model of colorectal distension. RESULTS: In mice, while orally given Trimebutine (the maleate salt, non-H2 S-releaser) only slightly reduced the nociceptive response to increasing pressures of colorectal distension, oral administration of GIC-1001 (the H2S-releaser) was able to significantly reduce nociceptive response to all noxious stimuli, in a dose-dependent manner. This effect of GIC-1001 was significantly better than the effects of its parent compound Trimebutine administered at equimolar doses. CONCLUSIONS: Taken together, these results demonstrated increased antinociceptive properties for GIC-1001 compared to Trimebutine, suggesting that this compound would be a better option to relieve from visceral pain and discomfort induced by lumenal distension.
An Automated Method for the Determination of Trimebutine and N-Mono-Desmethyl Trimebutine by On-Line Turbulent Flow Coupled with Liquid Chromatography-Tandem Mass Spectrometry in Human Plasma: Application to a Fatal Poisoning Case with Toxicokinetic Study.[Pubmed:26342056]
J Anal Toxicol. 2015 Nov-Dec;39(9):720-5.
A liquid chromatography-MS-MS turbulent flow on-line extraction method was developed for the determination of Trimebutine (TMB) and its main active metabolite N-mono-desmethylTrimebutine (norTrimebutine or nor-TMB) in human plasma. After protein precipitation and internal standard (IS, haloperidol-d4) addition, 50 microL of the supernatant were transferred onto a Cyclone-Turbo-Flow extraction column followed by an Hypersil PFP Gold analytical column. Detection was carried out on a triple quadrupole tandem mass spectrometer using positive electrospray ionization. The transitions used were m/z 388.0-->343.0, 374.0-->195.0 and 380.1-->169.0 for TMB, nor-TMB and IS, respectively. The method was validated over the concentration range of 10-1,000 ng/mL for both compounds. The accuracy evaluated at three concentrations was within 90.0-98.5% and the intra- and interday coefficient of variation's for the two molecules were <8.7%. The method was applied to a toxicokinetic study of a self-poisoning case with TMB in a 19-old girl. The concentration of TMB decreased from 747 to 77 ng/mL, while nor-TMB decreased from 9,745 to 205 ng/mL after 5 days and the fatal issue. This case confirms the literature underlining the potential toxicity of TMB, which has long time been considered as a harmless molecule.
Discovery of a novel trimebutine metabolite and its impact on N-desmethyltrimebutine quantification by LC-MS/MS.[Pubmed:25966011]
Bioanalysis. 2015;7(8):1007-15.
BACKGROUND: A failure in incurred sample reanalysis (ISR) for N-desmethylTrimebutine (NDMT), during the analysis of a Trimebutine-containing drug GIC-1001 Phase I study, led to the discovery of a never-before reported metabolite of Trimebutine. RESULTS: A positive bias for NDMT during the ISR and post-reconstitution stability evaluations indicated the presence of an unstable metabolite of NDMT. Precursor ion scans performed on freshly extracted samples enabled the identification of this metabolite to be the NDMT glucuronide conjugate and its fragmentation pattern suggested that the glucuronide moiety was attached at the N-terminal of NDMT. CONCLUSIONS: An acidification step was introduced in the extraction procedure to completely hydrolyze the glucuronide and measure the total NDMT in plasma, rendering this method a successful fit-for-purpose assay.
